GlobeNewswire Inc | Sep 1, 2021 08:30AM EDT

September 01, 2021

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings.

Investors and the general public are invited to listen to the Baird fireside chat, which will be accessible on the Events page under the Investors & Media section of theMyovantwebsite atwww.myovant.com.

AboutMyovant SciencesMyovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.Founded in 2016, we have two FDA-approved products. ORGOVYX(relugolix) was approved by theU.S. Food and Drug Administrationin 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review inEuropefor men with advanced prostate cancer.Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was approved in 2021 in theU.S.as MYFEMBREEas the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, and by the European Commission as RYEQOfor the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.The therapy has also completed Phase 3 registration-enabling studies for women with endometriosis and is being assessed for the prevention of pregnancy.We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction.Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website atwww.myovant.com. Follow@Myovanton Twitter andLinkedIn.

Investor Contact:Ryan CroweVice President, Investor RelationsMyovant Sciences, Inc.+1 (650) 781-9106investors@myovant.com

Media Contact:Albert LiaoDirector, Corporate CommunicationsMyovant Sciences, Inc.+1 (650) 410-3055media@myovant.com